您的购物车当前为空
STAT3-IN-15是一款有效、具口服活性的STAT3抑制剂,用于对抗特发性肺纤维化(IPF)。该化合物阻止STAT3磷酸化,同时抑制TGF-β1引起的上皮细胞迁移及变形,并防止上皮间质转化(EMT)。

STAT3-IN-15是一款有效、具口服活性的STAT3抑制剂,用于对抗特发性肺纤维化(IPF)。该化合物阻止STAT3磷酸化,同时抑制TGF-β1引起的上皮细胞迁移及变形,并防止上皮间质转化(EMT)。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 10,500 | 6-8周 | |
| 50 mg | ¥ 13,700 | 6-8周 | |
| 100 mg | ¥ 17,400 | 6-8周 |
STAT3-IN-15 相关产品
| 产品描述 | STAT3-IN-15, a potent and orally active inhibitor targeting STAT3, effectively combats idiopathic pulmonary fibrosis (IPF) by hindering STAT3 phosphorylation. Additionally, it impedes TGF-β1-induced migration and deformation of epithelial cells and prevents epithelial-mesenchymal transition (EMT), offering a multifaceted approach against IPF. |
| 分子量 | 422.42 |
| 分子式 | C20H17F3N2O3S |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容